People who are fully vaccinated against Covid-19 are highly protected against severe infection, hospitalization and death caused by the coronavirus. But Covid cases among the fully vaccinated — so-called “breakthrough” Covid cases — are still being seen among those who have had two doses.
Fully Vaccinated Getting Infected Covid-19
This is happening for a number of reasons, experts note. For a start, none of the vaccines being deployed in the U.S. or Europe are 100% effective at preventing infection. In addition, new Covid-19 strains such as the highly infectious delta variant — which is now prevalent around the world —have complicated the efficacy picture.
There is also incomplete data into how long immunity from Covid-19 lasts following vaccination. The alarm was raised over breakthrough Covid-19 cases when preliminary data in Israel — which had one of the fastest vaccination programs in the world — published in late July found that the Pfizer-BioNTech Covid-19 vaccine was just 40.5% effective at preventing symptomatic disease.
The analysis, which was carried out as the delta variant became the country’s dominant strain, still found that having two doses of the shot provided strong protection against severe illness and hospitalization, however, the country’s Health Ministry reported.
The data also appeared to show a waning effectiveness of the Pfizer-BioNTech shot too, with the vaccine only 16% effective against symptomatic infection for those individuals who had two doses of the shot back in January. For people that had received two doses by April, the efficacy rate (against symptomatic infection) stood at 79%, however.
But a study in England carried out from April to May found that, after two doses, the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease caused by the delta variant. Comparing the results is tricky, however, given differences in the nature of the vaccination programs in both countries (Israel gave all its adult population the Pfizer vaccine, for example, while in the U.K. there are several vaccines in use, with the Pfizer-BioNTech shot predominantly given to younger people) as well as differences in the study dates, Covid testing regimes and age groups.
Like the Israeli data, the English data also concluded that after two doses the Pfizer-BioNTech Covid-19 vaccine is 96% effective against hospitalization from the delta variant. Similarly, it found that the Oxford-AstraZeneca vaccine was 92% effective in preventing hospitalization after two doses. Initial vaccine efficacy data following clinical trials, released by Pfizer and BioNTech last year, showed that the vaccine was 95% effective.
Professor Lawrence Young, a virologist at the University of Warwick’s Medical School in the U.K., told CNBC that cases of Covid-19 in fully vaccinated people are a reminder that “no vaccine is 100% effective.” “There will always be a proportion of individuals who will still remain susceptible to infection and illness,” he said Monday.
“There are also two other factors that impact vaccine effectiveness: (1) waning immunity — we still don’t know how long vaccine-induced protective immunity lasts. This is very likely to be a factor in those elderly and more vulnerable individuals who were vaccinated early in the vaccine rollout program,” he noted.
The second factor, he added, related to “breakthrough infections in vaccinated individuals due to the more infectious delta variant” which added weight to the case for booster vaccination programs, he said. As yet, the jury is still out on booster programs with a decision yet to be made in the U.S. and U.K.